Related Experiment Video
Updated: Aug 5, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers
Simona Laurino1, Mariarita Brancaccio2, Tiziana Angrisano3
1IRCCS CROB, Centro di Riferimento Oncologico della Basilicata, 85028 Rionero in Vulture, Italy.
Abstract:
Gastric cancer, the second most common cause of death worldwide, is characterized by poor prognosis and low responsiveness to chemotherapy. Indeed, multidrug resistance, based mainly on cellular and molecular factors, remains one of the most limiting factors of the current approach to gastric cancer (GC) therapy. We employed a comprehensive gene expression analysis through data mining of publicly available databases to assess the role of the signal transducer and activator of transcription 3 (STAT3) in gastric cancer drug efficiency. It has been proposed that gastric cancer cells are less sensitive to these drugs because they develop resistance to these agents through activating alternative signalling pathways responsible for overcoming pharmacological inhibition. Our study evaluated the hypothesis that activating STAT3 signalling in response to cisplatin reduces the reaction to the drug. Consistent with this hypothesis, inhibition of interleukin 6 (IL-6)/STAT3 in combination therapy with cisplatin prevented both STAT3 activation and more lethality than induction by a single agent. The data suggest that the IL-6/STAT3 axis block associated with cisplatin treatment may represent a strategy to overcome resistance.
Insights
This study reveals that blocking the IL-6/STAT3 pathway enhances cisplatin chemotherapy effectiveness in gastric cancer. Inhibiting STAT3 signaling alongside cisplatin overcomes drug resistance, improving patient treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer (GC) is a leading cause of cancer mortality globally.
- Multidrug resistance significantly limits the efficacy of current GC chemotherapy.
- Identifying molecular mechanisms of resistance is crucial for improving treatment strategies.
Purpose of the Study:
- To investigate the role of Signal Transducer and Activator of Transcription 3 (STAT3) in gastric cancer drug resistance.
- To evaluate the hypothesis that STAT3 activation contributes to cisplatin resistance in GC.
- To explore the potential of targeting the IL-6/STAT3 axis to overcome chemotherapy resistance.
Main Methods:
- Comprehensive gene expression analysis using public database mining.
- Evaluation of STAT3 signaling activation in response to cisplatin treatment.
- Assessment of combination therapy involving IL-6/STAT3 inhibition and cisplatin.
Main Results:
- STAT3 signaling activation was observed in response to cisplatin.
- Inhibition of the IL-6/STAT3 pathway prevented STAT3 activation.
- Combination therapy with IL-6/STAT3 inhibition and cisplatin demonstrated enhanced cancer cell lethality compared to single agents.
Conclusions:
- The IL-6/STAT3 signaling axis plays a significant role in mediating cisplatin resistance in gastric cancer.
- Blocking the IL-6/STAT3 pathway in conjunction with cisplatin represents a promising strategy to enhance therapeutic efficacy.
- Targeting this axis may offer a novel approach to overcome multidrug resistance in GC treatment.
More Related Videos
Related Concept Videos
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
01:20The JAK-STAT Signaling Pathway
02:56Treatment Resistant Cancers